 |
6 Diseases |  |
0 Trials |
|
0 Trials |  |
8 News |  |
- GSK3117391 / GSK
Phase classification: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Oct 30, 2020
P2, N=3, Terminated, Sponsor: GlaxoSmithKline
Phase classification: P1/2 --> P2
- GSK3117391 / GSK
Phase classification: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Mar 26, 2019
P1/2, N=3, Terminated, Sponsor: GlaxoSmithKline
Phase classification: P1/2 --> P2 Phase classification: P2 --> P1/2
- GSK3117391 / GSK
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Feb 14, 2018
P2, N=3, Terminated, Sponsor: GlaxoSmithKline
Phase classification: P2 --> P1/2 N=40 --> 3 | Recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Nov 2017 | Trial completion date: Feb 2019 --> Nov 2017; The study was terminated following an internal review of the company's current research and development portfolio.
- GSK3117391 / GSK
PK/PD data, Trial primary completion date: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 27, 2017
P2, N=40, Recruiting, Sponsor: GlaxoSmithKline
N=40 --> 3 | Recruiting --> Terminated | Trial primary completion date: Feb 2019 --> Nov 2017 | Trial completion date: Feb 2019 --> Nov 2017; The study was terminated following an internal review of the company's current research and development portfolio. Trial primary completion date: May 2018 --> Feb 2019
- | GSK3117391 / GSK
Enrollment open, PK/PD data: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Jan 24, 2017
P2, N=40, Recruiting, Sponsor: GlaxoSmithKline
Trial primary completion date: May 2018 --> Feb 2019 Not yet recruiting --> Recruiting
- | GSK3117391 / GSK
New P2 trial, PK/PD data: Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis (clinicaltrials.gov) - Nov 17, 2016
P2, N=40, Not yet recruiting, Sponsor: GlaxoSmithKline
- GSK3117391 / GSK
Enrollment change, Trial termination: Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers (clinicaltrials.gov) - Jul 21, 2014
P1, N=64, Terminated, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting N=94 --> 64 | Recruiting --> Terminated; Following the emergence of an unexpected pharmacodynamic effect, the sponsor has decided to conclude the study early without fully achieving its objective
- ||| GSK3117391 / GSK
New P1 trial: Phase 1 Dose Escalating Study to Assess Safety, Tolerability, Food Effect and PK of CHR-5154 in Healthy Male Volunteers (clinicaltrials.gov) - Sep 2, 2013
P1, N=94, Recruiting, Sponsor: GlaxoSmithKline